MELBOURNE, Australia , Oct. 16, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thirteen abstract presentations featuring the Company's ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37 th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Hamburg from 19 – 23 October 2024 . Telix's extensive theranostic pipeline will be showcased in presentations covering: TLX250-CDx (Zircaix® [1] , 89 Zr-girentuximab) kidney cancer imaging, including first real-world clinical experience; TLX101 ( 131 I-iodofalan or 131 I-IPA) glioblastoma therapy; TLX66 ( 90 Y-besilesomab) bone marrow conditioning therapy; TLX252 ( 225 Ac-girentuximab) carbonic anhydrase IX (CAIX)-targeted alpha therapy; and SENSEI®, Lightpoint's robotic-assisted gamma probe.
Dr. David N. Cade , Telix Group Chief Medical Officer, said, "We are pleased to be able to so comprehensively showcase our pipeline at EANM – the largest gathering of nuclear medicine professionals worldwide – with a sponsored symposium, and abstracts accepted across Telix's late-stage theranostic programs in kidney and brain cancers, and in bone marrow conditioning.
As in previous years, it is an honour for us to support the EANM Sanjiv Sam Gambhir Young Investigator Award. This is an exciting opportunity for a junior physician or scientist to further develop their career in radiopharmaceutical.
